Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTZCRP3)

• DTT Name: ERK activator kinase (MEK)
• Synonyms: MEK; MAPKK; MAP kinase kinase
• Gene Name: MEK
• DTT Type: Successful target; [1]
• UniProt ID: NOUNIPROTAC
• TTD ID: T99031

Molecular Interaction Atlas (MIA) of This DTT

1 Approved Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ARRY-162	DM1P6FR	Melanoma	2C30	Approved	[1]

5 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
NFX-179	DM77XQT	Neurofibromatosis 1	LD2D.10	Phase 2	[2]
HL-085	DMJDVCW	Melanoma	2C30	Phase 1/2	[3]
BI 3011441	DMFJGUL	Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]
GDC-0623	DMDY08K	Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]
RG7304	DMGFAVQ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]

13 Patented Agent(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Azetidine derivative 2	DMTB3KS	N. A.	N. A.	Patented	[7]
Benzoheterocyclic compound 1	DM3K25J	N. A.	N. A.	Patented	[7]
Benzoimidazole derivative 1	DMUJFCK	N. A.	N. A.	Patented	[7]
Benzoimidazole derivative 2	DMHX5VO	N. A.	N. A.	Patented	[7]
N-(arylamino)sulfonamide derivative 1	DM8GJA7	N. A.	N. A.	Patented	[7]
P-toluenesulfonate derivative 1	DME57SJ	N. A.	N. A.	Patented	[7]
PMID28594589-Compound-TABLE3C1	DMLZV70	N. A.	N. A.	Patented	[7]
PMID28594589-Compound-TABLE3C12	DMPK7IU	N. A.	N. A.	Patented	[7]
PMID28594589-Compound-TABLE3C14	DM4KWVF	N. A.	N. A.	Patented	[7]
PMID28594589-Compound-TABLE3C2	DMVYG0U	N. A.	N. A.	Patented	[7]
Pyridinone compound 1	DM2GR5Q	N. A.	N. A.	Patented	[7]
Pyridopyrimidine derivative 1	DMTZK6V	N. A.	N. A.	Patented	[7]
Quinazolines and azaquinazoline derivative 1	DME24BI	N. A.	N. A.	Patented	[7]

References

• [1] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [2] Clinical pipeline report, company report or official report of NFlection Therapeutics
• [3] Current Development Status of MEK Inhibitors. Molecules. 2017 Sep 26;22(10):1551.
• [4] Clinical pipeline report, company report or official report of Boehringer Ingelheim.
• [5] Clinical pipeline report, company report or official report of Genentech (2011).
• [6] Clinical pipeline report, company report or official report of Roche.
• [7] MEK inhibitors in oncology: a patent review (2015-Present).Expert Opin Ther Pat. 2017 Aug;27(8):887-906.